IL13 and respiratory system disorder: In light of concerns over TH2 associated immunopathology with certain vaccines for respiratory viruses (vaccine associated enhanced respiratory disease (VAERD)), these levels of IL-13 produced concomitantly with such highly elevated IL-5 may make Addavax (MF59) a less optimal choice for an adjuvant tailored for SARS-CoV-2.